Reported 10 days ago
Aura Biosciences (NASDAQ:AURA), a small-cap biotechnology firm focused on developing immunotherapies for cancer, shows significant growth potential with an upside of approximately 244%, according to recent analysis. Despite being less prominent than large-cap stocks, small-cap stocks like AURA are considered valuable due to their ability to outperform larger companies historically, especially in niche markets. With promising clinical developments and increasing R&D investments, Aura is positioned to make significant strides in cancer treatment.
Source: YAHOO